TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for nucleic acids, NTPs and mRNA capping analogs. Since 1996, TriLink has been a pioneer in nucleic acid synthesis and manufacturing, adapting its expertise over the decades to meet the evolving needs of biopharma companies developing therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.

Biopharma companies turn to TriLink both as a critical supplier of modified nucleic acids and as a CDMO partner that helps them move from early research into clinical trials. TriLink offers scale-up expertise and unique mRNA, oligonucleotide and plasmid production capabilities, spanning products from discovery grade (RUO) to full GMP grade, backed by deep experience in technology transfer.